The Radiopharm Theranostics Limited (RADX) SEC filings page provides access to the company’s U.S. regulatory disclosures as a foreign private issuer. Radiopharm files reports on Form 20‑F and Form 6‑K under the Securities Exchange Act of 1934, often furnishing Australian Securities Exchange announcements as exhibits for U.S. investors.
Recent Form 6‑K filings reference clinical and corporate milestones, such as interim Phase 2b data for 18F‑RAD101 in brain metastases, progress in Phase 1 trials of 177Lu‑RAD202 and 177Lu‑RAD204, ethics approval for the RAD402 prostate cancer trial, and U.S. FDA IND clearance for RV‑01 (Betabart). Other 6‑K submissions include notices of annual and extraordinary general meetings, results of shareholder votes, director interest notices, quarterly cash flow reports and presentations to investors.
Through this page, users can review how Radiopharm reports on its radiopharmaceutical pipeline, including imaging and therapeutic candidates targeting FASN, HER2, PD‑L1, αvβ6‑integrin, KLK3 and B7H3. Filings may also reference capital raisings, cash runway commentary and supply agreements for key radioisotopes used in clinical trials.
Stock Titan enhances these documents with AI-powered summaries that highlight the main points of lengthy filings, helping readers quickly understand trial updates, board and governance changes, and financing terms. Real‑time ingestion from EDGAR means new 6‑K and 20‑F submissions appear promptly, while integrated views of director interest notices and meeting results help track governance and potential insider‑related changes without manually reading every exhibit.
Radiopharm Theranostics has filed a Form 6-K to report the signing of a significant supply agreement with Cyclotek for 161Tb-KLK3-mAb, as announced on the Australian Securities Exchange on June 24, 2025.
The filing consists of an announcement made to the Australian Securities Exchange regarding the supply agreement, which has been attached as Exhibit 99.1 to the Form 6-K. The company files annual reports under Form 20-F and is not subject to Rule 12g3-2(b) under the Securities Exchange Act of 1934.
This Form 6-K and its exhibits are not considered "filed" for Securities Exchange Act purposes and will not be automatically incorporated by reference into future securities filings unless specifically referenced. The document was signed by Company Secretary Phillip Hains.